Article
Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.
Nature communications - 18 Jun 2024
Dans Madeline G, Boulet Coralie, Watson Gabrielle M, Nguyen William, Dziekan Jerzy M, Evelyn Cindy, Reaksudsan Kitsanapong, Mehra Somya, Razook Zahra, Geoghegan Niall D, Mlodzianoski Michael J, Goodman Christopher Dean, Ling Dawson B, Jonsdottir Thorey K, Tong Joshua, Famodimu Mufuliat Toyin, Kristan Mojca, Pollard Harry, Stewart Lindsay B, Brandner-Garrod Luke, Sutherland Colin J, Delves Michael J, McFadden Geoffrey I, Barry Alyssa E, Crabb Brendan S, de Koning-Ward Tania F, Rogers Kelly L, Cowman Alan F, Tham Wai-Hong, Sleebs Brad E, Gilson Paul R
Abstract excerpt
With resistance to most antimalarials increasing, it is imperative that new drugs are developed. We previously identified an aryl acetamide compound, MMV006833 (M-833), that inhibited the ring-stage development of newly invaded merozoites. Here, we select parasites resistant to M-833 and identify mutations in the START lipid transfer protein (PF3D7_0104200, PfSTART1). Introducing PfSTART1 mutations into wildtype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
